Nan van Geloven on Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
Nan van Geloven, Assistant Professor at Leiden University Medical Center, reposted from JAMA on LinkedIn:
”NEW PAPER
“Regular predictions are not suited for supporting individual treatment decisions. Combining prediction with causal inference is needed instead.”
Telling is one thing, doing is another.
In this new JAMA paper we put our money where our mouth is and applied causal inference to develop and evaluate a prediction model that estimates risks under different treatment options, supporting treatment decisions in preterm infants.
Highly rewarding to get the chance to put our newly developed methods in action, together with a great team of clinicians and epidemiologists.”
JAMA shared on LinkedIn:
”Among preterm infants with severe thrombocytopenia, this modeling study found substantial variation among individuals in predicted benefits and harms of prophylactic platelet transfusion based on their current clinical characteristics.”
Read the full article in JAMA.
Article: Individualized Prediction of Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
Authors: Hilde van der Staaij, Ilaria Prosepe, Camila Caram-Deelder, Ruth H. Keogh, Emöke Deschmann, Christof Dame, Wes Onland, Sandra A. Prins, Florian Cassel, Esther J. d’Haens, Elke van Westering-Kroon, Peter Andriessen, Sabine L. Vrancken, Christian V. Hulzebos, Daniel C. Vijlbrief, Suzanne F. Fustolo-Gunnink, Karin Fijnvandraat, Enrico Lopriore, Johanna G. van der Bom, Nan van Geloven
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2025, 11:43Wolfgang Miesbach: Jan Astermark at the BIC 2025 Presented Potentially the First Oral FVIII Mimetic Treatment for Hemophilia A
-
Sep 30, 2025, 06:43Sara García Barcenilla: What Better Way to Celebrate ''World ITP Day'' Then With The Interview of Nora Butta and Daniel Aníbal García-Diego
-
Sep 30, 2025, 06:42Courtney Battaglia: AFib Can Cause Racing Heartbeat or Fatigue and Also Raises The Risk of Stroke!
-
Sep 29, 2025, 22:44Pall T. Onundarson on Correlation Between Plasma Levels of DOACs and Both Thromboembolic and Bleeding Events
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 30, 2025, 06:45Robert Mikulik and Colleagues Show Differences in Acute Ischemic Stroke Treatment
-
Sep 30, 2025, 06:40Cihan Ay: Can AI Match Thrombosis Experts?
-
Sep 29, 2025, 19:56Luisa Hora de Carvalho and Colleagues Highlight The Challenges in Evaluating Thromboembolic Risk in Acute Leukemia
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 11:48Nan van Geloven on Platelet Transfusion Outcomes in Preterm Infants With Severe Thrombocytopenia
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 19:39Louise Bannon: Today is World Heart Day, And It's Deeply Personal For Me
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe